Published in final edited form as:

Neuroscience. 2014 May 16; 267: 166–176. doi:10.1016/j.neuroscience.2014.02.043.

Respiratory phenotypes are distinctly affected in mice with common Rett syndrome mutations MeCP2 T158A and R168X

John M Bissonnette^{1,2}, Laura R Schaevitz³, Sharon J Knopp¹, and Zhaolan Zhou⁴

¹Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, OR, USA

²Department of Cell and Developmental Biology, Oregon Health & Science University, Portland, OR, USA

³Department of Biology, Tufts University, Medford, MA 02155, USA

⁴Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

Abstract

Respiratory disturbances are a primary phenotype of the neurological disorder, Rett syndrome (RTT), caused by mutations in the X-linked gene encoding methyl-CpG-binding protein 2 (MeCP2). Mouse models generated with null mutations in *Mecp2* mimic respiratory abnormalities in RTT girls. Large deletions, however, are seen in only ~10% of affected human individuals. Here we characterized respiration in heterozygous females from two mouse models that genetically mimic common RTT point mutations, a missense mutation T158A (*Mecp2*^{T158A/+}) or a nonsense mutation R168X (*Mecp2*^{R168X/+}). MeCP2 T158A shows decreased binding to methylated DNA, while MeCP2 R168X retains the capacity to bind methylated DNA but lacks the ability to recruit complexes required for transcriptional repression. We found that both *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} heterozygotes display augmented hypoxic ventilatory responses and depressed hypercapnic responses, compared to wild type controls. Interestingly, the incidence of apnea was much greater in *Mecp2*^{R168X/+} heterozygotes, 189 per hour, than *Mecp2*^{T158A/+} heterozygotes, 41 per hour. These results demonstrate that different RTT mutations lead to distinct respiratory phenotypes, suggesting that characterization of the respiratory phenotype may reveal functional differences between MeCP2 mutations and provide insights into the pathophysiology of RTT.

Keywords

Rett syndrome; Apnea; hypoxia; hypercapnia; MeCP2; Transcriptional repression domain

© 2014 IBRO. Published by Elsevier Ltd. All rights reserved.

Corresponding author: John M. Bissonnette, MD, Department of Obstetrics and Gynecology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road; L-458, Portland, Oregon, USA, Phone: 503 494 2101; Fax: 503 494 5296, bissonne@ohsu.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

Rett syndrome (RTT) is a neurological disorder that affects approximately 1 in 10,000 girls. It is caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2), a modulator of gene transcription (Amir et al., 1999) (Guy et al., 2011). To date, more than 200 different mutations in *MECP2* have been identified in RTT cases (Bienvenu and Chelly, 2006) (Van den Veyver and Zoghbi, 2001). The majority of these, however, are point mutations clustered within or near one of three conserved functional domains of *MeCP2* (the methyl-CpG binding domain [MBD], the nuclear localization signals [NLS], and the transcriptional repression domain [TRD]) suggesting the importance of these domains to protein function.

Respiratory abnormalities, characterized by frequent apnea and an irregular inter-breath interval, are a main phenotype of RTT (Katz et al., 2009) (Ramirez et al., 2013). Thus far, the majority of respiratory studies in mouse models of RTT have utilized males with *Mecp2* null mutations. While this strategy avoids the issue of mosaic expression of MeCP2 due to random X-inactivation, it does not address the fact that patients with the disorder are almost exclusively heterozygous females; hemizygous male patients typically die *in utero* or shortly thereafter (Bienvenu and Chelly, 2006). Respiratory studies in *Mecp2* deficient female mice (*Mecp2*^{-/+}) have, to date, been confined to animals with deletions of exons III and IV (referred to as *Mecp2*^{Bird}) (Bissonnette and Knopp, 2006) (Abdala et al., 2010) (Samaco et al., 2013) or exon III (referred to as *Mecp2*^{Jaе}) (Schmid et al., 2012). These large deletions, however, are seen in only ~10% of affected individuals (Katz et al., 2012). Animal models of RTT are important tools for preclinical studies; therefore, it is desirable to expand investigations to include the respiratory phenotype of RTT mouse models with common RTT mutations. In doing so, we gain a better understanding of which breathing abnormalities are most robustly affected across mutation types. In addition, these studies may provide insight into how different MeCP2 domains contribute to respiratory phenotypes in RTT and how different RTT mutations impair the functional domains of MeCP2.

In this study, we characterized the respiratory phenotype of two mouse models whose mutations are among two of the eight most commonly found in human cases of RTT (Archer et al., 2007) (Bebbington et al., 2008) (Colvin et al., 2004) (Neul et al., 2008). In the first mouse model, conversion of threonine 158 to methionine or alanine (T158M or T158A) results in a mutated protein with decreased binding to methylated DNA and that is degraded more rapidly than normal MeCP2 (Goffin et al., 2011). In the second model, a knockin of a stop codon at arginine 168, mimicking a nonsense R168X mutation, yields an early truncated MeCP2 protein that retains the MBD domain, but the TRD domain is lost (Brendel et al., 2007) (Lawson-Yuen et al., 2007). We characterized the respiratory patterns in female heterozygotes with either the *MeCP2* T158A (*Mecp2*^{T158A/+}) or *MeCP2* R168X (*Mecp2*^{R168X/+}) mutation. In addition, it has previously been shown that *Mecp2* deficient mice have an augmented ventilatory response to hypoxia (Bissonnette and Knopp, 2006) (Voituron et al., 2009) (Ward et al., 2011) and a depressed carbon dioxide chemosensitivity (Zhang et al., 2011) (Toward, 2013). Accordingly we have also examined the hypoxic ventilatory and CO₂ responses in the *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} female mice.

Methods

The experiments were approved by the Institutional Animal Care and Use Committee at Oregon Health Science University and were in agreement with the National Institutes of Health “Guide for the Care and Use of Laboratory Animals”.

Animals

Mecp2^{T158A/+} and their *Mecp2*^{+/+} littermates were generated by crossing *Mecp2*^{T158A/+} females to wild type males (*Mecp2*^{+/y}). The 8 *Mecp2*^{T158A/+} females were from 5 litters and each mouse had 1 or 2 *Mecp2*^{+/+} littermates that allowed direct comparisons. These mice were on a C57Bl/6 background. *Mecp2*^{R168X/+} and *Mecp2*^{+/+} mice (Lawson-Yuen et al., 2007) were a kind gift from Joanne E Berger-Sweeney at Tufts University. These mice were on a mixed C57Bl/6 × 129S6/SvEv Tac background.

Plethysmography

Respiratory frequency, tidal volume (V_T) and their product minute ventilation (V_E) were determined in a body plethysmograph (Mortola and Noworaj, 1983, Bissonnette and Knopp, 2006). Briefly, individual unanesthetized animals were placed in a 65mL chamber with their head exposed through a close fitting hole in Parafilm®. A pneumotachograph (Mortola and Noworaj, 1983) was connected to the chamber and a differential pressure transducer (Model PT5A, Grass Instrument Co., West Warwick, RI, USA). The pressure signal was integrated to give tidal volume. Volume changes were calibrated by injecting known amounts of air into the chamber. The analog signal from the transducer was amplified, converted to digital, displayed on a monitor, and stored to disc by computer for later analysis. The studies were begun after the animal was given time to become adjusted to the chamber. A cone was fitted over the animal's head that allowed inspired gases to be delivered. For hypoxia experiments gas at the nose was rapidly, 5 sec, changed in succession from air to 8% O₂ for 5 min and then returned to air for a 5 min recovery period. Similarly for CO₂ sensitivity, after 5 min in air the animal was exposed in succession to 5 min of 1, 3 and then 5% CO₂, balance air. The last 2 min of each 5 min exposure to air and to CO₂ were used for analysis as used previously in (Davis et al., 2006). Segments of the record that contained apnea were not used to calculate frequency. Minute ventilation in response to 8% O₂ and to graded CO₂ is reported as percent increase relative to the control. Recorded data was analyzed with custom functions in Chart v5.5.6 (AD Instruments, Inc., Colorado Springs, CO, USA). The hypoxia and hypercarbia studies were conducted when the animals were between 9 and 14 months of age.

Analysis

Apnea was defined as interval between breaths (T_{TOT}) > 1.0 sec. Respiratory cycle irregularity score was obtained from absolute $(T_{TOTn} - T_{TOTn+1}) / T_{TOTn+1}$, and is expressed as the variance (Viemari et al., 2005). Results are given as mean ± SEM. Inspiratory time (T_I), expiratory time (T_E) and their sum (T_{TOT}) as well as tidal volume (V_T) were determined from representative segments of 100 consecutive breaths (Figure 1) using custom functions in Igor Pro® (WaveMetrics, Inc. Lake Oswego, OR, USA). Single comparisons between genotypes such as for brain weight and baseline respiratory

parameters were analyzed with unpaired student t-tests. The relative effect of hypoxia and CO₂ on T_I compared to T_E within strains was determined with paired t-tests. Repeated measurements, such as for the three levels of CO₂, were made with a Mixed Model ANOVA with percentage CO₂ as the repeated measure and genotype as the between group factor. Significance was determined using Sigma stat 3.1 programs with $P < 0.05$.

3. Results

Animal characteristics

Mecp2^{T158A/+} (n=8) and *Mecp2*^{+/+} (n=8) female mice were studied at monthly intervals from 4 months to a year of age. Average weight, 29.3 ± 1.1 gms, of the mutant mice did not differ from that of wild type animals, 27.1 ± 1.8 gms ($t = 1.034$, $p = 0.32$, unpaired t-test). As is characteristic of *Mecp2* null mice, brain weights at 12 to 14 months of age were significantly smaller in *Mecp2*^{T158A/+} than *Mecp2*^{+/+} controls (432 ± 5 vs 500 ± 9 mg; $t = 6.508$, $p < 0.0001$). Studies in *Mecp2*^{R168X/+} female mice (n=8) started at ages between 11.5 and 12.4 months and continued to 15.5 months. Body weight in *Mecp2*^{R168X/+} mice was not statistically different from wild type at 12.5 months (22.6 ± 0.7 vs 24.4 ± 0.7 gm respectively). Similar to *Mecp2*^{T158A/+}, the brain weights of *Mecp2*^{R168X/+} mice were reduced compared to *Mecp2*^{+/+} controls (396 ± 5 vs 450 ± 6 mg; $t = -7.052$, $p < 0.0001$).

Respiratory pattern in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice

All 8 *Mecp2*^{T158A/+} animals exhibited an increased incidence of apnea (Figures 1 and 2A) that occurred between 5.6 and 10.8 months of age (mean: 7.7 ± 0.7 months); although the age at onset varied between mice. Increased apnea incidence did not persist, rather the rates returned to a level that did not differ from that in *Mecp2*^{+/+} mice within 1 month in 5 *Mecp2*^{T158A/+} mice and within 2 months in the remaining 3 *Mecp2*^{T158A/+} mice. Since the onset of apnea did not occur at the same age in individual *Mecp2*^{T158A/+} mice, we normalized the peak incidence across age and plotted apnea rates in the months preceding and following the peak (Figure 2A). Breath interval irregularity at the time of peak apnea incidence was significantly greater in *Mecp2*^{T158A/+} mice compared to *Mecp2*^{+/+} ($F = 12.93$, $p = 0.029$; Figure 2B), but not in the months preceding or following peak incidence (data not shown). Baseline expiratory time (T_E) in *Mecp2*^{T158A/+} mice was significantly prolonged compared to WT, but T_I, T_{TOT} and frequency were not significantly different (Figure 2C and Table 1).

The respiratory pattern in *Mecp2*^{R168X/+} mice was followed from 11.5 to 15.5 months. Due to age variation in the acquired *Mecp2*^{R168X/+} cohort, respiration was assessed in 5 *Mecp2*^{R168X/+} mice at 11.5 months and in 8 mice at 12.5 months and after. Respiration in wild type mice (n=7) from the R168X colony was determined at 11.5 and 14.5 months. The incidence of apnea in wild type mice at 11.5 months (9.7 ± 5.3/Hr) and 14.5 months (1.6 ± 0.9/Hr) was compared to apnea in *Mecp2*^{R168X/+} at 11.5 and 12.5 months and 13.5, 14.5 and 15.5 months respectively. At 11.5 months, apnea was greater in all *Mecp2*^{R168X/+} (Figures 1 and 3A) than wild type and remained elevated throughout all 5 months of assessment ($F = 10.6$, $p = 0.0004$ for 11.5 to 12.5 months and $F = 3.59$, $p = 0.041$ for 13.5 to 15.5 months). Furthermore, inter-breath interval was irregular ($F = 16.67$, $p = 0.013$) (Figure 3B).

Mecp2^{R168X/+} mice show significantly prolonged T_I, T_E and T_{TOT} and significantly reduced frequency ($F = 51.71, p < 0.0001$) relative to wild type littermates (Table 1 and Figure 3C).

In marked contrast to *Mecp2*^{T158A/+} mice, the incidence of apnea in *Mecp2*^{R168X/+} animals was significantly greater (41 ± 5 vs 189 ± 43 /Hr; $t = 69.55, p < 0.0001$; unpaired t-test). The irregular breathing patterns and decreased frequency were also more severely affected in *Mecp2*^{R168X/+} mice, relative to wild type, than in *Mecp2*^{T158A/+} animals. Irregularity was 7.2 ± 0.7 fold greater than wild type in *Mecp2*^{R168X/+} compared to 3.5 ± 0.4 in *Mecp2*^{T158A/+} ($t = 1.55, p = 0.016$; unpaired t-test). Respiratory frequency was significantly lower in *Mecp2*^{R168X/+} (0.59 ± 0.04 that of wild type) than in *Mecp2*^{T158A/+} (0.92 ± 0.05 that of wild type) ($t = 5.43, p = 0.0001$; unpaired t-test).

Hypoxic ventilatory response in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice

The hypoxic ventilatory response was augmented in females with both the T158A and R168X MeCP2 mutation. *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} heterozygous females exhibited an increase in minute ventilation in the first minute of breathing 8% oxygen that significantly exceeded that of wild type mice (Figures 4A and 4B and Table 2). The greater increase in minute ventilation was entirely due to a larger increase in respiratory rate in heterozygous females with no difference in tidal volume (Figure 5A and 5D). On return to air, after the 5 min hypoxic exposure, ventilation remained elevated in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice while it rapidly returned to baseline in wild type mice. Additionally, respiratory frequency in *Mecp2*^{+/+} mice decreased below that of the pre-hypoxia baseline (Figure 5), a characteristic of rodents termed post-hypoxic frequency decline (Dick and Coles, 2000). In the 1st minute of recovery, frequency fell 22 ± 8 bpm in wild type while it remained elevated 17 ± 7 bpm above baseline in *Mecp2*^{T158A/+} animals ($F = 4.757; p = 0.047$). Similarly in *Mecp2*^{R168X/+} mice respiratory frequency was 31 ± 23 bpm above baseline in the 1st min of recovery while it fell 38 ± 18 bpm in wild type ($F = 5.66; p = 0.037$). Moreover, the decrease in frequency during recovery in wild type mice tended to be due to longer expiratory times than at baseline (T_E: $30 \pm 7\%$ for T158A *Mecp2*^{+/+} and $35.5 \pm 18.9\%$ for R168X *Mecp2*^{+/+}) than in lengthened inspiratory times (T_I: $12.6 \pm 4.2\%$ for T158A *Mecp2*^{+/+} and $21.9 \pm 17.3\%$ for R168X *Mecp2*^{+/+}).

CO₂ chemosensitivity in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice

Chemosensitivity was depressed in both *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice. The relative increase in minute ventilation in both mutant strains was significantly less at 1, 3 and 5% CO₂ (Figure 5) (*Mecp2*^{T158A}: $F = 20.589; p < 0.0001$ and *Mecp2*^{R168X}: $F = 21.81; p < 0.0001$). The depression was mostly pronounced at 1% CO₂ (71.4%) compared to that at 3 and 5% (55.8 and 55.5% respectively) in *Mecp2*^{T158A/+} mice. In *Mecp2*^{R168X/+} mice, depression at the lowest CO₂ was also most prominent, 78.2% at 1% CO₂ compared to 51.2 and 30.2% at 3 and 5% CO₂, respectively. In general, wild type mice showed increased respiratory rate and tidal volume above baseline at all levels of CO₂ (Figure 7). In contrast, respiratory rate only increased at 5% CO₂ in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice (Table 3). CO₂ did not elicit an increase in tidal volume in any CO₂ level in mutant animals (Figure 7). In comparison to wild type mice, the increase in frequency for *Mecp2*^{T158A/+} mice tended to be less at 3% CO₂ and was significantly less at 5% CO₂, while it was significantly

less in *Mecp2*^{R168X/+} at 3% CO₂ (Figure 7). The increase in respiratory rate at 5% CO₂ across strains and genotypes was mainly the result of a significant shortening of T_E as compared to T_I. T_E was shortened to a greater extent than T_I in *Mecp2*^{T158A/+} (16.7 ± 0.9 vs $11.6 \pm 1.6\%$; $t = 3.196$, $p = 0.015$, paired T-test) and *Mecp2*^{R168X/+} heterozygous females (23 ± 5.6 vs $12.2 \pm 4.3\%$; $t = 3.11$, $p = 0.021$) as well as their wild type littermates (T158A *Mecp2*^{+/+}: 18.1 ± 2.9 vs $10.7 \pm 2.5\%$; $t = 3.716$, $p = 0.0075$ and R168X *Mecp2*^{+/+}: 25.9 ± 2.4 vs $14.6 \pm 3.1\%$; $t = 5.11$, $p = 0.002$).

Discussion

The principal findings in this study are that heterozygous female mice with RTT mutation MeCP2 T158A: 1) develop a modest increase in the incidence of apnea between 5.6 and 10.8 months of age, followed by a normal breathing pattern thereafter; 2) have an augmented hypoxic ventilatory response and 3) depressed CO₂ chemosensitivity. In contrast, mice with RTT mutation MeCP2 R168X: 1) have a pronounced incidence of apnea equal to that in *Mecp2* null heterozygotes that is sustained from 11.5 through 15.5 months of age and 2) display hypoxic and hypercapnic ventilatory responses similar to *Mecp2*^{T158A/+} mice and *Mecp2* null heterozygotes. Thus, different RTT mutations result in similar age-dependent breathing abnormalities but with distinct severity.

Mecp2^{T158A/+} and *Mecp2*^{R168X/+} mice have distinct respiratory phenotypes

The respiratory pattern was less significantly affected in *Mecp2*^{T158A/+} than *Mecp2*^{R168X/+} heterozygous mice. Interestingly, the incidence of apnea (range 24 to 68/hr) in the *Mecp2*^{T158A/+} mice was considerably less than that in *Mecp2*^{R168X/+} (range 64 to 421/hr) and in older *Mecp2*^{Bird} or *Mecp2*^{Jae} females measured in prior studies (average 80 to 160/hr) (Abdala et al., 2010) (Knopp, Bissonnette unpublished). Thus, *Mecp2*^{R168X/+} female mice had an incidence of apnea more similar to that measured in mice with large deletions. The irregular breathing pattern in *Mecp2*^{R168X/+}, 7 fold that of wild type, is greater than that observed in *Mecp2*^{Jae/+} and *Mecp2*^{Bird/+} heterozygous females (5 and 4 fold respectively) (Knopp, Bissonnette unpublished); while that in *Mecp2*^{T158A/+} (3.5 fold) is somewhat less. Differences in apnea incidence and respiratory irregularity between mutation types suggest that the respiratory phenotypes are closely coupled to the functions of MeCP2. While breathing problems are reported to be common in patients with both T158M and R168X mutations (de Lima FT, 2009) (Halbach et al., 2012), a distinction with respect to severity has not been documented in clinical studies.

The divergent respiratory phenotypes of *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} heterozygous mice share similarities and differences with the phenotype in RTT patients as well as other mouse models of RTT. Rett syndrome subjects have been reported to have irregular breathing and increased respiratory frequency with a significantly shorter T_{TOT}, in which the shortening of T_E contributes more than shortening of T_I, compared to normal girls (Weese-Mayer et al., 2006). Similar to the irregular breathing patterns reported in RTT subjects, breath-to-breath irregularities were prominent in both the *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} heterozygous mice. However, the normal respiratory frequency we observed in *Mecp2*^{T158A/+} mice and the decrease in respiratory frequency in *Mecp2*^{R168X/+} mice differ

from the human findings. In contrast, an increase in frequency was found in *Mecp2^{Jae/+}* heterozygous female mice (Song et al., 2011) (Schmid et al., 2012). The frequency in *Mecp2^{Bird/+}* heterozygous female mice, on two different background strains, however, was the same as their respective wild type littermates (Samaco et al., 2013). While breathing irregularity is a common phenotype, respiratory frequency in mouse models of RTT appears to depend on the nature of the MeCP2 mutation.

Prolonged pauses in breathing are another common feature of the respiratory phenotype in RTT. A variety of types of breathing arrests having been reported in awake RTT subjects. Traces of chest wall movement in conjunction with respiration showed that arrest of breathing most commonly occurs at the end of inspiration with chest wall held in an expanded position or a neutral position (Weese-Mayer et al., 2006) (Stettner et al., 2008) (Julu et al., 2001). Cheyne-stokes respiration and central apnea are far less common in awake RTT subjects whereby breathing arrest occurs following expiration (Southall et al., 1988) (Julu et al., 2001). The pattern of apnea following expiration in *Mecp2^{T158A/+}* and *Mecp2^{R168X/+}* female mice (Figure 1) differs from the common human observations, indicating that these mice may better model the more uncommonly described apneas.

Two other studies have found an asymptomatic as well as a symptomatic population of *Mecp2* deficient female mice (Song et al., 2011) (Schmid et al., 2012). As noted above both studies used *Mecp2^{Jae/+}* females. Song and coauthors reported that, when studied under anesthesia plus vagotomy, half of the mice were symptomatic, defined as an increase in respiratory frequency. These mice did not have apnea. Schmid et al. examined unanaesthetized mice and found that at 12 weeks of age half had an incidence of apnea that exceeded wild type. These results differ from that we have observed in *Mecp2^{T158A/+}* and *Mecp2^{R168X/+}* mice, all of which were symptomatic. Given that *Mecp2* is an X-linked gene, random X-chromosome inactivation (XCI) results in somatic mosaicism and the pattern of XCI likely varies between different cells types and individual subjects. A previous study reported that as many as 72% of neurons may express the wild type allele in the *Mecp2^{Jae/+}* heterozygous mice (Braunschweig et al., 2004). Thus, unbalanced XCI and/or the XCI state of progenitors cells giving rise to critical cell mass in the brain stem may contribute to the lack of respiratory symptoms in a subpopulation of *Mecp2^{Jae/+}* mice.

The differences in severity of the respiratory phenotype between *Mecp2^{T158A/+}* and *Mecp2^{R168X/+}* female mice are consistent with differences in severity of other behavioral phenotypes. Previous work reported that mice with the MeCP2 T158A mutation develop behavioral phenotypes that are similar to, but less severe than the phenotype of *Mecp2* null mice (Goffin et al., 2011). The MeCP2 T158A protein shows reduced stability and decreased binding to methylated DNA, but retains the ability to interact with co-repressor complexes (Ho et al., 2008) (Goffin et al., 2011). Both the mild respiratory phenotype, described here, and the less severe behavioral phenotype, reported previously, support that T158A is a partial loss-of-function mutation. The R168X mutation, however, results in respiratory abnormalities and a behavioral phenotype more similar, but not identical, to that of *Mecp2* null mice (Schaevitz et al., 2013). The largely truncated R168X protein carries a partial NLS and lacks the TRD domain for interaction with co-repressors (Stancheva et al., 2003) (Kumar et al., 2008). Given that the respiratory phenotype of *Mecp2^{R168X/+}* females is

similar to that of *Mecp2^{Jae/+}* or *Mecp2^{Bird/+}* with large deletions of the MBD or MBD and TRD respectively, it suggests that the complete loss of either of these functional domains results in a severe respiratory phenotype. Additionally, it is possible that the truncated R168X protein, though expressed at a low level (Lawson-Yuen 2007), may have a dominant negative effect on MeCP2 function. Recently, Bird and colleagues reported that mice carrying a MeCP2 R306C missense mutation in the TRD domain, in which the interaction between MeCP2 and NCoR repressor complex is specifically disrupted, develop RTT-like phenotypes (Lyst et al., 2013), supporting the functional significance of the TRD domain. The respiratory phenotypes in those R306C knockin mice have yet to be characterized.

Unexpectedly, the longitudinal study of respiratory in *Mecp2^{T158A/+}* heterozygous females revealed a novel transient increase in apneas. Longitudinal studies of respiration in heterozygous *Mecp2^{Jae/+}* and *Mecp2^{Bird/+}* female mice have, to our knowledge, not been reported over the time span included in this study. Thus it is difficult to determine if the transient increase in apneas is a general feature of *Mecp2* deficient female mice or is unique to *Mecp2^{T158A/+}* animals. A crosssectional retrospective examination of apneas in *Mecp2^{Bird/+}* mice between 5.5 and 18.5 months of age showed a consistent pattern of apneas (Bissonnette and Knopp, unpublished) (n=32). While we were only able to follow *Mecp2^{R168X/+}* mice from 11.5 to 15.5 months of age, there were no significant changes in apnea incidence suggesting that, of the mouse models studied to date, the transient increase and improvement in apneas over time may be unique to the *Mecp2^{T158A/+}* heterozygous females. Importantly, in RTT patients, cross sectional observations suggest that abnormal breathing patterns improve with advancing age (Lugaresi et al., 1985) (Julu et al., 2001). Thus *Mecp2^{T158A/+}* heterozygous female mice may be a useful model for understanding the molecular mechanisms behind improvements in respiration.

Hypoxic ventilatory response is altered in *Mecp2^{T158A/+}* and *Mecp2^{R168X/+}* mice

The augmented response to hypoxia noted in both *Mecp2^{T158A/+}* and *Mecp2^{R168X/+}* mutants is due to an exaggerated increase in respiratory frequency as compared to wild type littermates and is similar to that reported previously in *Mecp2^{Bird}* female (Bissonnette and Knopp, 2006) and male mutant mice (Bissonnette and Knopp, 2006) (Voituron et al., 2009) (Ward et al., 2011) (Ren et al., 2012). An increase in excitability of nucleus tractus solitarius (NTS) neurons may underlie the augmented response. Kline and coauthors (Kline et al., 2010) demonstrated that stimulation of the tractus produced larger excitatory post-synaptic currents (EPSCs) in slices from *Mecp2* null male mice compared to controls. Bath applied brain derived neurotrophic factor (BDNF) reduced the exaggerated EPSCs in the *Mecp2*-null mice. Furthermore, the absence of a post-hypoxic decline in respiratory frequency (PHFD) (Fig. 4) robustly distinguished both *Mecp2^{T158A/+}* and *Mecp2^{R168X/+}* mice from their respective wild type controls. In wild type mice, PHFD is mediated mainly through the prolongation of expiratory time (T_E) compared to baseline as shown previously (Dick and Coles, 2000)(Song and Poon, 2009). PHFD requires intact signaling from neurons in the ventrolateral pons and depends on NMDA receptor function (Dick and Coles, 2000). While impaired NMDA receptor signaling has been demonstrated in symptomatic, but not asymptomatic, *Mecp2^{Jae/+}* female mice (Song et al., 2011), the extent to which alterations in

NMDA function and EPSCs in the NTS contribute to hypoxic ventilatory response in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice has yet to be studied.

CO₂ chemosensitivity response is altered in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice

The depressed hypercapnic ventilatory response displayed by both *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} is similar to that reported in *Mecp2*^{Bird} null male and female heterozygous mice (Zhang et al., 2011) (Toward, 2013). Both breath frequency and tidal volume changes were significantly lower in *Mecp2*^{Bird} null males than wild types when mice were exposed to low concentrations of CO₂ (1, 2 and 3%), but not at 6% and 9% CO₂ (Zhang et al., 2011). Similarly, in this study, the increase in minute ventilation was most depressed at lower CO₂ concentrations (~70% at 1% CO₂ versus 30–50% at 3% and 5% CO₂) in both *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} heterozygous females. The depressed ventilatory response to CO₂ in heterozygous mutants is the result of minimal increases in both respiratory rate and tidal volume as compared to baseline. In the wild type mice of both strains, respiratory rate and tidal volume increased at all levels of CO₂. In contrast, in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mutant mice, respiratory rate significantly increased only at 5% CO₂ while tidal volume remained unchanged. The increased respiratory frequency demonstrated only at 5% CO₂ in both wild type and heterozygous mutants was the result of decreased expiratory (T_E) rather than inspiratory (T_I) time. The blunted chemosensitivity in *Mecp2* deficient mice appears to be connected to low levels of the neuromodulators norepinephrine and serotonin. Blocking norepinephrine reuptake markedly improved the response to CO₂ (Zhang et al., 2011) and increasing brain serotonin restored the CO₂ response to the level of wild type mice (Toward, 2013). Thus, it is likely that elevation of norepinephrine and/or serotonin may restore CO₂ response in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice as well. During episodes of hyperventilation, CO₂ concentration significantly decreases in RTT subjects (Southall et al., 1988) (Smeets et al., 2006). As in mouse models, if RTT individuals have an elevated CO₂ apnea threshold, they would experience a cessation of breathing at carbon dioxide levels that sustain ventilation in unaffected individuals.

Summary and conclusions

In conclusion this detailed characterization of the respiratory phenotype in heterozygous *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice shows that they share a number of similarities with mice containing large deletions in *Mecp2* but with distinct severity. Mice with both T158A and R168X mutations exhibit an increased incidence of apnea, and an irregular breath cycle. The irregular breathing pattern is consistent with what has been found in RTT subjects, but the reduced respiratory frequency in *Mecp2*^{R168X/+} mice and the onset of apnea after expiration in both strains differ from the common breathholding following inspiration in RTT subjects. In addition, we found that abnormal respiration is ameliorated with advancing age in the *Mecp2*^{T158A/+} strain. By comparing *Mecp2*^{T158A/+} mice at their pre-symptomatic, symptomatic and recovered stages, these mice may prove to be very valuable tools for understanding the pathophysiology of respiratory disorders in RTT. The severe phenotype seen in *Mecp2*^{R168X/+} heterozygous females are well suited for pre-clinical treatment trials that utilize respiration as a primary outcome measure, though classification of individual animal respiratory severity is necessary prior to treatment trials. Furthermore, the augmented

hypoxic ventilatory response and depressed hypercapnic response exhibited by both the *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} and previously in mice containing large deletions suggest that these respiratory phenotypes in particular, may be robust outcome measures for pre-clinical trials.

Acknowledgments

The authors thank Julian FR Paton for valuable suggestions on the manuscript, James Maylie for writing custom applications in Igor Pro® and Joseph Coyle for generously providing the *Mecp2*^{R168X} mice to the Berger-Sweeney Laboratory. This work was supported by the Rett Syndrome Research Trust, NewLife Foundation for Disabled Children (UK) (JMB), International Rett Syndrome Foundation (JMB and ZZ) and a NIH grant NS058391 (ZZ). ZZ is a Pew Scholar in Biomedical Science.

References

- Abdala AP, Dutschmann M, Bissonnette JM, Paton JF. Correction of respiratory disorders in a mouse model of Rett syndrome. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:18208–18213. [PubMed: 20921395]
- Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nature genetics*. 1999; 23:185–188. [PubMed: 10508514]
- Archer H, Evans J, Leonard H, Colvin L, Ravine D, Christodoulou J, Williamson S, Charman T, Bailey ME, Sampson J, de Klerk N, Clarke A. Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation. *Journal of medical genetics*. 2007; 44:148–152. [PubMed: 16905679]
- Bebbington A, Anderson A, Ravine D, Fyfe S, Pineda M, de Klerk N, Ben-Zeev B, Yatawara N, Percy A, Kaufmann WE, Leonard H. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. *Neurology*. 2008; 70:868–875. [PubMed: 18332345]
- Bienvenu T, Chelly J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. *Nat Rev Genet*. 2006; 7:415–426. [PubMed: 16708070]
- Bissonnette JM, Knopp SJ. Separate respiratory phenotypes in methyl-CpG-binding protein 2 (*Mecp2*) deficient mice. *Pediatric research*. 2006; 59:513–518. [PubMed: 16549521]
- Braunschweig D, Simcox T, Samaco RC, LaSalle JM. X-Chromosome inactivation ratios affect wild-type MeCP2 expression within mosaic Rett syndrome and *Mecp2*^{-/+} mouse brain. *Human molecular genetics*. 2004; 13:1275–1286. [PubMed: 15115765]
- Brendel C, Belakhov V, Werner H, Wegener E, Gartner J, Nudelman I, Baasov T, Huppke P. Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. *J Mol Med (Berl)*. 2007; 89:389–398. [PubMed: 21120444]
- Colvin L, Leonard H, de Klerk N, Davis M, Weaving L, Williamson S, Christodoulou J. Refining the phenotype of common mutations in Rett syndrome. *Journal of medical genetics*. 2004; 41:25–30. [PubMed: 14729826]
- Davis SE, Solhied G, Castillo M, Dwinell M, Brozoski D, Forster HV. Postnatal developmental changes in CO2 sensitivity in rats. *J Appl Physiol*. 2006; 101:1097–1103. [PubMed: 16794027]
- de Lima FTBD, Schwartzman JS, Pozzi MC, Kok F, Juliano Y, Pereira LV. Genotype-phenotype correlation in Brazilian Rett Syndrome Patients. *Arq Neuropsiquiatr*. 2009; 67:577–584. [PubMed: 19722030]
- Dick TE, Coles SK. Ventrolateral pons mediates short-term depression of respiratory frequency after brief hypoxia. *Respiration physiology*. 2000; 121:87–100. [PubMed: 10963767]
- Goffin D, Allen M, Zhang L, Amorim M, Wang IT, Reyes AR, Mercado-Berton A, Ong C, Cohen S, Hu L, Blendy JA, Carlson GC, Siegel SJ, Greenberg ME, Zhou Z. Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. *Nature neuroscience*. 2011; 15:274–283.

- Guy J, Cheval H, Selfridge J, Bird A. The role of MeCP2 in the brain. *Annu Rev Cell Dev Biol.* 2011; 27:631–652. [PubMed: 21721946]
- Halbach NS, Smeets EE, van den Braak N, van Roozendaal KE, Blok RM, Schrandt-Stumpel CT, Frijns JP, Maaskant MA, Curfs LM. Genotype-phenotype relationships as prognosticators in Rett syndrome should be handled with care in clinical practice. *Am J Med Genet A.* 2012; 158A:340–350. [PubMed: 22190343]
- Ho KL, McNae IW, Schmiedeberg L, Klose RJ, Bird AP, Walkinshaw MD. MeCP2 binding to DNA depends upon hydration at methyl-CpG. *Molecular cell.* 2008; 29:525–531. [PubMed: 18313390]
- Julu PO, Kerr AM, Apartopoulos F, Al-Rawas S, Engerstrom IW, Engerstrom L, Jamal GA, Hansen S. Characterisation of breathing and associated central autonomic dysfunction in the Rett disorder. *Archives of disease in childhood.* 2001; 85:29–37. [PubMed: 11420195]
- Katz DM, Berger-Sweeney JE, Eubanks JH, Justice MJ, Neul JL, Pozzo-Miller L, Blue ME, Christian D, Crawley JN, Giustetto M, Guy J, Howell CJ, Kron M, Nelson SB, Samaco RC, Schaevitz LR, St Hillaire-Clarke C, Young JL, Zoghbi HY, Mamounas LA. Preclinical research in Rett syndrome: setting the foundation for translational success. *Dis Model Mech.* 2012; 5:733–745. [PubMed: 23115203]
- Katz DM, Dutschmann M, Ramirez JM, Hilaire G. Breathing disorders in Rett syndrome: progressive neurochemical dysfunction in the respiratory network after birth. *Respir Physiol Neurobiol.* 2009; 168:101–108. [PubMed: 19394452]
- Kline DD, Ogier M, Kunze DL, Katz DM. Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice. *J Neurosci.* 2010; 30:5303–5310. [PubMed: 20392952]
- Kumar A, Kamboj S, Malone BM, Kudo S, Twiss JL, Czymmek KJ, LaSalle JM, Schanen NC. Analysis of protein domains and Rett syndrome mutations indicate that multiple regions influence chromatin-binding dynamics of the chromatin-associated protein MECP2 in vivo. *Journal of cell science.* 2008; 121:1128–1137. [PubMed: 18334558]
- Lawson-Yuen A, Liu D, Han L, Jiang ZI, Tsai GE, Basu AC, Picker J, Feng J, Coyle JT. Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice. *Brain research.* 2007; 1180:1–6. [PubMed: 17936729]
- Lugaresi E, Cirignotta F, Montagna P. Abnormal breathing in the Rett syndrome. *Brain & development.* 1985; 7:329–333. [PubMed: 4061768]
- Mortola JP, Noworaj A. Two-sidearm tracheal cannula for respiratory airflow measurements in small animals. *J Appl Physiol.* 1983; 55:250–253. [PubMed: 6885578]
- Neul JL, Fang P, Barrish J, Lane J, Caeg EB, Smith EO, Zoghbi H, Percy A, Glaze DG. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. *Neurology.* 2008; 70:1313–1321. [PubMed: 18337588]
- Ramirez JM, Ward CS, Neul JL. Breathing challenges in Rett Syndrome: Lessons learned from humans and animal models. *Respir Physiol Neurobiol.* 2013
- Ren J, Ding X, Funk GD, Greer JJ. Anxiety-related mechanisms of respiratory dysfunction in a mouse model of Rett syndrome. *J Neurosci.* 2012; 32:17230–17240. [PubMed: 23197715]
- Samaco RC, McGraw CM, Ward CS, Sun Y, Neul JL, Zoghbi HY. Female Mecp2(+/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. *Human molecular genetics.* 2013; 22:96–109. [PubMed: 23026749]
- Schaevitz LR, Gomez NB, Zhen DP, Berger-Sweeney JE. MeCP2 R168X male and female mutant mice exhibit Rett-like behavioral deficits. *Genes Brain Behav.* 2013; 12:732–740. [PubMed: 24283265]
- Schmid DA, Yang T, Ogier M, Adams I, Mirakhor Y, Wang Q, Massa SM, Longo FM, Katz DM. A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. *J Neurosci.* 2012; 32:1803–1810. [PubMed: 22302819]
- Smeets EE, Julu PO, van Waardenburg D, Engerstrom IW, Hansen S, Apartopoulos F, Curfs LM, Schrandt-Stumpel CT. Management of a severe forceful breather with Rett syndrome using carbogen. *Brain & development.* 2006; 28:625–632. [PubMed: 16765005]

- Song G, Tin C, Giacometti E, Poon CS. Habituation without NMDA Receptor-Dependent Desensitization of Hering-Breuer Apnea Reflex in a Mecp2 Mutant Mouse Model of Rett Syndrome. *Front Integr Neurosci*. 2011; 5:6. [PubMed: 21629824]
- Song G, Poon CS. Lateral parabrachial nucleus mediates shortening of expiration during hypoxia. *Respir Physiol Neurobiol*. 2009; 165:1–8. [PubMed: 18992853]
- Southall DP, Kerr AM, Tirosh E, Amos P, Lang MH, Stephenson JB. Hyperventilation in the awake state: potentially treatable component of Rett syndrome. *Archives of disease in childhood*. 1988; 63:1039–1048. [PubMed: 3140736]
- Stancheva I, Collins AL, Van den Veyver IB, Zoghbi H, Meehan RR. A mutant form of MeCP2 protein associated with human Rett syndrome cannot be displaced from methylated DNA by notch in *Xenopus* embryos. *Molecular cell*. 2003; 12:425–435. [PubMed: 14536082]
- Stettner GM, Huppke P, Gartner J, Richter DW, Dutschmann M. Disturbances of breathing in Rett syndrome: results from patients and animal models. *Advances in experimental medicine and biology*. 2008; 605:503–507. [PubMed: 18085325]
- Toward M, Abdala AP, Knopp SJ, Paton JFR, Bissonnette JM. Increasing brain serotonin corrects CO2 chemosensitivity in methyl-CpG-binding protein 2 (Mecp2) deficient mice. *Experimental physiology*. 2013; 98:842–849. [PubMed: 23180809]
- Van den Veyver IB, Zoghbi HY. Mutations in the gene encoding methyl-CpG-binding protein 2 cause Rett syndrome. *Brain & development*. 2001; 23 (Suppl 1):S147–151. [PubMed: 11738862]
- Viemari JC, Roux JC, Tryba AK, Saywell V, Burnet H, Pena F, Zanella S, Bevengut M, Barthelemy-Requin M, Herzing LB, Moncla A, Mancini J, Ramirez JM, Villard L, Hilaire G. Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. *J Neurosci*. 2005; 25:11521–11530. [PubMed: 16354910]
- Voituron N, Zanella S, Menuet C, Dutschmann M, Hilaire G. Early breathing defects after moderate hypoxia or hypercapnia in a mouse model of Rett syndrome. *Respir Physiol Neurobiol*. 2009; 168:109–118. [PubMed: 19524074]
- Ward CS, Arvide EM, Huang TW, Yoo J, Noebels JL, Neul JL. MeCP2 is critical within HoxB1-derived tissues of mice for normal lifespan. *J Neurosci*. 2011; 31:10359–10370. [PubMed: 21753013]
- Weese-Mayer DE, Lieske SP, Boothby CM, Kenny AS, Bennett HL, Silvestri JM, Ramirez JM. Autonomic nervous system dysregulation: breathing and heart rate perturbation during wakefulness in young girls with Rett syndrome. *Pediatric research*. 2006; 60:443–449. [PubMed: 16940240]
- Zhang X, Su J, Cui N, Gai H, Wu Z, Jiang C. The disruption of central CO2 chemosensitivity in a mouse model of Rett syndrome. *Am J Physiol Cell Physiol*. 2011; 301:C729–738. [PubMed: 21307341]

Highlights

- The first characterization of breathing in female mice with common Rett mutations
- Both T158A and R168X mice exhibit abnormal hypoxic and hypercapnic responses
- Apnea incidence, irregular breath cycle and decreased breathing rate are more severe in R168X than in T158A mice
- Respiratory phenotypes in R168X mice are similar to those in *Mecp2*-null mice
- Abnormal respiratory patterns are ameliorated with advancing age in T158A mice

Fig 1.

Breathing in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice. Diagram illustrating calculation of inspiratory (T_I), expiratory (T_E), total time (T_{TOT}), and tidal volume (V_T) of a sample breath. Representative traces in *Mecp2*^{T158A/+} (top 2 traces continuous record) and *Mecp2*^{R168X/+} bottom 2 traces. Calibration is the same for all traces. Apnea is more frequent and respiratory frequency is slower in *Mecp2*^{R168X/+} compared to *Mecp2*^{T158A/+} mice.

Fig 2.

Respiratory pattern in *Mecp2*^{T158A/+} mice. A. Apnea incidence normalized to the peak incidence that occurred at 7.7 ± 0.7 months shown as the months preceding and following the peak $n=8$ for *Mecp2*^{T158A/+} and for *Mecp2*^{+/+}; *** $F = 35.59$; $p < 0.0001$ (ANOVA, Tukey post hoc test). B. Irregularity score at time of peak incidence in apnea. Score calculated from absolute $(T_{TOTn} - T_{TOTn+1})/T_{TOTn+1}$, and expressed as the variance (Viemari et al., 2005). * $F = 12.93$; $p = 0.029$. C. Respiratory frequency.

Fig. 3.

Respiratory pattern in *Mecp2*^{R168X/+} mice. A. Incidence of apnea; *Mecp2*^{R168X/+} n varied from 5 to 8. Apnea in *Mecp2*^{+/+} averaged 9.7 ± 5.3 / hr at 11.5 months and 1.6 ± 0.9 / hr at 14.5 n=7; * $F = 10.607$, $p = 0.0004$ for 11.5 and 12.5 months; $F = 3.594$, $p = 0.041$ for 13.5 to 15.5 months. B. Average irregularity score between 11.5 and 15.5 months. * $F = 16.67$; $p = 0.013$ C. Average respiratory frequency between 11.5 and 15.5 months, * $F = 51.71$; $p < 0.0001$.

Fig 4.

Hypoxic ventilatory response in *Mecp2^{T158A/+}* and *Mecp2^{R168X/+}* mice. A. *Mecp2^{T158A/+}* and *Mecp2^{+/+}* mice, n=8 for each genotype; Hypoxia: $F = 10.87$; min 1 $p = 0.0044$; min 3; $p = 0.043$. Recovery: min 6, $p = 0.041$; min 7 $p = 0.018$; min 10 $p = 0.048$. B. *Mecp2^{R168X/+}* mice n=6 and *Mecp2^{+/+}* mice n=7: Hypoxia: $F = 5.16$; min 1 $p = 0.0039$; min 3 $p = 0.057$; min 4 $p = 0.046$; min 5 $p = 0.024$. Recovery: min 6 $p = 0.0013$; min 7 $p = 0.014$; min 8 $p = 0.068$.

Fig. 5. Respiratory frequency and tidal volume in hypoxia and recovery. Data from the 1st min of hypoxia and 1st min of recovery in air are presented. A. Baseline frequency in *Mecp2*^{T158A/+} mice (n=8) and *Mecp2*^{+/+} (n=8). B. Change in frequency in *Mecp2*^{T158A/+} mice in hypoxia and recovery. C. Baseline frequency in *Mecp2*^{R168X/+} (n=6) and *Mecp2*^{+/+} (n=7). D. Change in frequency in *Mecp2*^{R168X/+} mice. E. Baseline tidal volume in *Mecp2*^{T158A/+} mice. F. Change in tidal volume in *Mecp2*^{T158A/+} mice. G. Baseline tidal volume in *Mecp2*^{R168X/+} mice. H. Change in tidal volume in *Mecp2*^{R168X/+} mice. *p<0.05 and ** p<0.01 compared to baseline. † p<0.05 compared to *Mecp2*^{+/+}.

Fig 6.

Hypercapnic ventilatory response in *Mecp2*^{T158A/+} and *Mecp2*^{R168X/+} mice. A. *Mecp2*^{T158A/+} and *Mecp2*^{+/+}, n=8 for each genotype. $F = 20.59$; 1% $p = 0.019$; 3% $p = 0.0019$; 5% $p < 0.0001$. B. *Mecp2*^{R168X/+} n=6 and *Mecp2*^{+/+} n=7. $F = 21.81$; 1% $p = 0.0002$; 3% $p = 0.001$; 5% $p = 0.033$.

Fig. 7.

Respiratory frequency and tidal volume response to carbon dioxide (CO₂). A. Frequency in *Mecp2*^{T158A/+} mice (n=8) and *Mecp2*^{+/+} (n=8). B. Change in frequency in *Mecp2*^{T158A/+} mice in response to CO₂. C. Baseline frequency in *Mecp2*^{R168X/+} (n=7) and *Mecp2*^{+/+} (n=7). D. Frequency response to CO₂ in *Mecp2*^{R168X/+} mice. E. Baseline tidal volume in *Mecp2*^{T158A/+} mice. F. Change in tidal volume in *Mecp2*^{T158A/+} mice. G. Baseline tidal volume in *Mecp2*^{R168X/+} mice. H. Change tidal volume in *Mecp2*^{R168X/+} mice. *p<0.05 and ** p<0.01 compared to baseline. † p<0.05 and †† p<0.01 compared to *Mecp2*^{+/+}.

Table 1

Respiratory pattern in *MeCP2^{T158A/+}* and *MeCP2^{R168X/+}* mice.

Strain	N	T _I ms	T _E ms	T _{TOT} ms	Rate bpm
<i>MeCP2^{+/+}</i>	8	135±5	139±4	275±8	220±7
<i>MeCP2^{T158A/+}</i>	8	145±6	157±7	301±12	202±8
F		1.22	5.09	2.12	3
P		0.29	0.041	0.099	0.105
<i>MeCP2^{+/+}</i>	7	135±5	147±5	283±10	214±7
<i>MeCP2^{R168X/+}</i>	8	212±15	276±2	487±31	127±7
F		21.13	35.24	33.29	64.62
P		0.0005	<0.0001	<0.0001	<0.0001

T_I: inspiratory time; T_E: expiratory time; T_{TOT}: total respiratory time; bpm: breaths per minute